$An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer$

An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer

10.1089/thy.2019.0269

Saved in:

Bibliographic Details
Main Authors:	Bible, Keith C, Menefee, Michael E, Lin, Chia-Chi Josh, Millward, Michael J, Maples, William J, Goh, Boon Cher, Karlin, Nina J, Kane, Madeleine A, Adkins, Douglas R, Molina, Julian R, Donehower, Ross C, Lim, Wan-Teck, Flynn, Patrick J, Richardson, Ronald L, Traynor, Anne M, Rubin, Joseph, LoRusso, Patricia M, Smallridge, Robert C, Burton, Jill K, Suman, Vera J, Kumar, Aditi, Voss, Jessie S, Rumilla, Kandalaria M, Kipp, Benjamin R, Chintakuntlawar, Ashish, Harris, Pamela, Erlichman, Charles
Other Authors:	MEDICINE
Format:	Article
Language:	English
Published:	MARY ANN LIEBERT, INC 2024
Subjects:	Science & Technology Life Sciences & Biomedicine Endocrinology & Metabolism pazopanib radioactive iodine refractory differentiated thyroid cancer kinase inhibitor DOUBLE-BLIND SUNITINIB CARCINOMA MACROCYTOSIS TRIAL
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/248918
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Similar Items

Vascular endothelial growth factor inhibitors and cognitive impairment: Evidence and controversies
by: Ng, T., et al.
Published: (2014)

HPLC-MS/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma
by: Toh, Yi Long, et al.
Published: (2020)

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer
by: Bible, K.C., et al.
Published: (2016)

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H
by: Bible, K.C., et al.
Published: (2016)

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study
by: Bible, K.C., et al.
Published: (2016)

HPLC-MS/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma
by: Toh, Y.L., et al.
Published: (2021)

Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network
by: Shantakumar, S, et al.
Published: (2020)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
by: Barrios, C.H., et al.
Published: (2014)

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
by: Ang, Y.L.E., et al.
Published: (2021)

Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity
by: Choudhury, Y, et al.
Published: (2020)

EXPLORING THE ROLE OF PHARMACOKINETIC ALTERATIONS IN TYROSINE KINASE INHIBITORS (TKIS)-ASSOCIATED TOXICITIES
by: TEO YI LING
Published: (2015)

Tubulocystic renal carcinoma: A clinical perspective
by: Hora, M., et al.
Published: (2016)

Phototoxic reaction induced by pazopanib
by: Siriorn Udompanich, et al.
Published: (2019)

Evaluation of a new direct radioimmunoassay for serum thyroid peroxidase and thyroglobulin antibodies.
by: L. O. Chailurkit, et al.
Published: (2018)

Iodine supplementation of mildly iodine-deficient adults lowers thyroglobulin: A randomized controlled trial
by: Ma, Z.F, et al.
Published: (2020)

DESIGN OF POLYMERIC MICELLAR NANOCOMPLEXES COMPOSED OF GREEN TEA CATECHIN DERIVATIVES FOR CANCER THERAPY
by: NUNNARPAS YONGVONGSOONTORN
Published: (2016)

Dried blood spot thyroglobulin as a biomarker of iodine status in pregnant women
by: Sara Stinca, et al.
Published: (2018)

Correlation between "Point mutation and truncation of thyroglobulin" and "Their patterns of export and iodination"
by: Piyanuch Jongsamak
Published: (2023)

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic merkel cell carcinoma
by: Davids, M., et al.
Published: (2011)

Pitfall in immunohistochemical staining for thyroglobulin in case of thyroid metastasis from lung carcinoma
by: Napatt Kanjanahattakij, et al.
Published: (2018)

The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma
by: Tan, M.-H., et al.
Published: (2014)

Corrigendum: Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity
by: Choudhury, Y., et al.
Published: (2020)

Protein disulfide isomerase acts as a molecular chaperone in the intracellular retention of mouse mutant thyroglobulin
by: Piyanuch Jongsamak
Published: (2018)

A phase II study of pazopanib in asian patients with recurrent/metastatic nasopharyngeal carcinoma
by: Lim, W.-T., et al.
Published: (2016)

Defective protein folding and intracellular retention of thyroglobulin-R19K mutant as a cause of human congenital goiter
by: Paul S. Kim, et al.
Published: (2018)

คู่มือปฏิบัติงาน เรื่อง แนวทางการตรวจวิเคราะห์ Thyroglobulin (Tg) ด้วยเครื่องตรวจวิเคราะห์อัตโนมัติ
by: อัญชลี ไหลพิริยกุล
Published: (2019)

Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
by: Haaland, B, et al.
Published: (2020)

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry
by: De Groot, S, et al.
Published: (2020)

Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
by: Yadav, Kritika, et al.
Published: (2023)

Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib
by: Noppadon Kongsuphon, et al.
Published: (2020)

Sunitinib-associated hyperammonemic encephalopathy successfully managed with higher intensity conventional hemodialysis: A case report
by: Haroon, S, et al.
Published: (2021)

Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study
by: Erman Mustafa, et al.
Published: (2022)

Gossip, epistemology, and power : knowledge underground
by: Adkins, Karen
Published: (2020)

Greenpeace volunteers
by: Ferry, July, et al.
Published: (2002)

Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer
by: Wong A.L.A., et al.
Published: (2020)

Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study (BMC Cancer, (2021), 21, 1, (1021), 10.1186/s12885-021-08738-z)
by: Mustafa Erman, et al.
Published: (2022)

A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group
by: Moore, M.M., et al.
Published: (2011)

'Prechronous' metastasis in clear cell renal cell carcinoma: A case report
by: Poon, E, et al.
Published: (2020)

Investigations on real-time charging and discharging pricing of electric vehicles
by: Muhamad Danish Karlin Bin Mohamed Isa
Published: (2024)

Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?
by: Ou, S.-H.I, et al.
Published: (2020)